Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients

6/24/24 4:16:59 PM ET

$CORT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CORT alert in real time by email

Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes"
With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes
Results demonstrate a hypercortisolism prevalence rate of 24 percent in this patient population

Get the next $CORT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CORT

Date	Price Target	Rating	Analyst
11/6/2023	$29.00 → $38.00	Hold → Buy	Truist
4/11/2023	$25.00	Market Perform	SVB Securities
4/4/2023	$27.00	Overweight	Piper Sandler
2/15/2023	$35.00 → $22.00	Buy → Hold	Jefferies
8/1/2022	$30.00	Buy → Hold	Truist
7/27/2022	$21.00 → $35.00	Hold → Buy	Jefferies
6/27/2022	$30.00 → $34.00	Buy	Canaccord Genuity
2/2/2022	$30.00	Buy	Canaccord Genuity

More analyst ratings

$CORT
Market Insights

Live Market Insights

Piper Sandler Reiterates Overweight on Corcept Therapeutics, Maintains $35 Price Target
Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and maintains $35 price target.
7/1/24 9:44:13 AM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care
Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes"With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetesResults demonstrate a hypercortisolism prevalence rate of 24 percent in this patient population
6/24/24 4:16:59 PM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care
6 Analysts Have This To Say About Corcept Therapeutics
During the last three months, 6 analysts shared their evaluations of Corcept Therapeutics (NASDAQ:CORT), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.67, a high estimate of $65.00, and a low estimate of $38.00. Surpassing the previous average price targe
6/17/24 3:00:59 PM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update
Revenue of $182.5 million, a 48 percent increase over the same period in 2023 Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 million Net income per common share of $0.41 (diluted), compared to $0.28 in third quarter 2023 Cash and investments of $547.6 million as of September 30, 2024 Results from Phase 3 GRADIENT trial support findings from pivotal Phase 3 GRACE study; new drug application (NDA) of relacorilant to be submitted this quarter Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by mod
10/30/24 4:05:00 PM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutic
10/23/24 4:05:00 PM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. Financial Results Revenue of $163.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 millionNet income per common share of $0.32 (diluted), compared to $0.25 in second quarter 2023Cash and investments of $492.5 million as of June 30
7/29/24 4:05:00 PM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care

Corcept Appoints Roberto Vieira as President, Oncology
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o
1/29/24 8:00:00 AM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care
Corcept Appoints Monica Tellado as President, Emerging Markets
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science
11/1/23 8:00:00 AM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care
Corcept Therapeutics Announces Appointment of Three Senior Leaders
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid
4/7/22 4:05:00 PM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care

$CORT
Press Releases

Fastest customizable press release news feed in the world

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update
Revenue of $182.5 million, a 48 percent increase over the same period in 2023 Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 million Net income per common share of $0.41 (diluted), compared to $0.28 in third quarter 2023 Cash and investments of $547.6 million as of September 30, 2024 Results from Phase 3 GRADIENT trial support findings from pivotal Phase 3 GRACE study; new drug application (NDA) of relacorilant to be submitted this quarter Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by mod
10/30/24 4:05:00 PM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutic
10/23/24 4:05:00 PM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. Financial Results Revenue of $163.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 millionNet income per common share of $0.32 (diluted), compared to $0.25 in second quarter 2023Cash and investments of $492.5 million as of June 30
7/29/24 4:05:00 PM ET
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care

Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients

Chat with this insight

Recent Analyst Ratings for $CORT

$CORT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Swisher Daniel N Jr exercised 2,200 shares at a strike of $12.13 and sold $131,736 worth of shares (2,200 units at $59.88) (SEC Form 4)

Chief Development Officer Guyer William exercised 10,000 shares at a strike of $21.65 and sold $489,700 worth of shares (10,000 units at $48.97) (SEC Form 4)

Chief Development Officer Guyer William exercised 10,000 shares at a strike of $21.65 and sold $462,800 worth of shares (10,000 units at $46.28) (SEC Form 4)

$CORT Market Insights

Live Market Insights

Piper Sandler Reiterates Overweight on Corcept Therapeutics, Maintains $35 Price Target

Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients

6 Analysts Have This To Say About Corcept Therapeutics

$CORT SEC Filings

$CORT Financials

Live finance-specific insights

$CORT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CORT Large Ownership Changes

This live feed shows all institutional transactions in real time.

$CORT Leadership Updates

Live Leadership Updates

SEC Form 10-Q filed by Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Corcept Therapeutics Incorporated

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics upgraded by Truist with a new price target

SVB Securities initiated coverage on Corcept Therapeutics with a new price target

Piper Sandler initiated coverage on Corcept Therapeutics with a new price target

SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

Corcept Appoints Roberto Vieira as President, Oncology

Corcept Appoints Monica Tellado as President, Emerging Markets

Corcept Therapeutics Announces Appointment of Three Senior Leaders

$CORT Press Releases

Fastest customizable press release news feed in the world

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Recent Analyst Ratings for
$CORT

$CORT
Insider Trading

$CORT
Market Insights

$CORT
SEC Filings

$CORT
Financials

$CORT
Analyst Ratings

$CORT
Large Ownership Changes

$CORT
Leadership Updates

$CORT
Press Releases